Top

European Journal of Nuclear Medicine and Molecular Imaging

25-09-2024 | Positron Emission Tomography | Original Article

Exploration the feasibility and additional value of [¹⁸F]FDG/[⁶⁸Ga]Ga-FAPI-04 dual-low-activity-tracer one-stop total-body PET imaging at 34 min post-injection of [⁶⁸Ga]Ga-FAPI-04

Authors: Zhe Zheng, Yibo He, Wujian Mao, Haojun Yu, Ha Wu, Runjun Yang, Huaping Gao, Pengcheng Hu, Hongcheng Shi

Published in: European Journal of Nuclear Medicine and Molecular Imaging

Abstract

Objectives

To validate the feasibility of one-stop 2-[¹⁸F]fluoro-2-deoxy-D-glucose ([¹⁸F]FDG) and [⁶⁸Ga]Ga-fibroblast activation protein inhibitor-04 ([⁶⁸Ga]Ga-FAPI-04) dual-low-activity-tracer positron emission tomography/computed tomography (PET/CT) at 34 min post-injection of [⁶⁸Ga]Ga-FAPI-04 and explore its additional value.

Methods

Thirty pairs of patients with suspected malignancies who underwent dual-tracer imaging were enrolled in this retrospective study. The images were reconstructed at 34–39 and 50–60 min after additional injection of [⁶⁸Ga]Ga-FAPI-04 (in one-stop FDG-FAPI PET/CT, named PET_FDG, PET_D34–39, and PET_D50–60; in the 2-day protocol, named PET_FDG’, PET_F34–39, and PET_F50−60, respectively). Tumour-to-normal ratios (TNR) of lesions in PET_FDG, PET_D34−39, and PET_D50−60 and TNR of lesions in PET_F34−39 and PET_F50−60 were evaluated separately. To evaluate the potential added value of one-stop FDG-FAPI PET/CT over the 2-day protocol, TNRs of PET_FDG, PET_D34−39, and PET_D50−60 were compared with PET_F34−39. The lesion detectability of the two imaging protocols was evaluated by chi-square test.

Results

Comparing FAPI-weighted PET (PET_D34−39 and PET_D50−60) and single-tracer imaging (PET_FDG) in one-stop FDG-FAPI PET/CT, TNRs of FAPI-weighted PET were higher than those of PET_FDG. PET_D34−39 and PET_D50−60 showed similar performance in lesion detectability and TNRs (all P > 0.05). In the 2-day protocol, there are no statistically significant differences in TNRs of all lesions at PET_F34−39 and PET_F50−60. Comparing one-stop FDG-FAPI PET/CT with the 2-day protocol, TNRs of PET_F34−39 were significantly higher than those of PET_FDG but lower than those of PET_D34−39 and PET_D50−60. Lesion detectability in the one-stop FDG-FAPI PET/CT was higher than that in the 2-day protocol. The average radiation dose in one-stop FDG-FAPI PET/CT was significantly lower than that in the 2-day protocol (P<0.001).

Conclusion

One-stop FDG-FAPI PET/CT at 34 min could provide sufficient information to meet clinical diagnosis and showed better lesion detectability than that in the 2-day protocol.

Available only for authorised users

Puré E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37(32):4343–57. https://doi.org/10.1038/s41388-018-0275-3.CrossRefPubMedPubMedCentral

Peltier A, Seban RD, Buvat I, Bidard FC, Mechta-Grigoriou F. Fibroblast heterogeneity in solid tumors: from single cell analysis to whole-body imaging. Semin Cancer Biol. 2022;86(Pt 3):262–72. https://doi.org/10.1016/j.semcancer.2022.04.008.CrossRefPubMed

Gilardi L, Airò Farulla LS, Demirci E, Clerici I, Omodeo Salè E, Ceci F. Imaging cancer-associated fibroblasts (CAFs) with FAPi PET. Biomedicines. 2022;10:523. https://doi.org/10.3390/biomedicines10030523.CrossRefPubMedPubMedCentral

Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022;49(8):2844–68. https://doi.org/10.1007/s00259-022-05706-y.CrossRefPubMedPubMedCentral

Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, et al. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol. 2023;96(1142):20220463. https://doi.org/10.1259/bjr.20220463.CrossRefPubMed

Çermik TF, Ergül N, Yılmaz B, Mercanoğlu G. Tumor imaging with 68Ga-DOTA-FAPI-04 PET/CT: comparison with 18F-FDG PET/CT in 22 different cancer types. Clin Nucl Med. 2022;47(4):e333–9. https://doi.org/10.1097/RLU.0000000000004073.CrossRefPubMed

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–5. https://doi.org/10.2967/jnumed.119.227967.CrossRefPubMedPubMedCentral

Moradi F, Iagaru A, Will. FAPI PET/CT replace FDG PET/CT in the next decade? Counterpoint-no, not so fast. AJR Am J Roentgenol. 2021;216(2):307–8. https://doi.org/10.2214/AJR.20.23794.CrossRefPubMed

Roth KS, Voltin CA, van Heek L, Wegen S, Schomäcker K, Fischer T, et al. Dual-Tracer PET/CT protocol with [(18)F]-FDG and [(68)Ga]Ga-FAPI-46 for cancer imaging: a proof of concept. J Nucl Med. 2022;63(11):1683–6. https://doi.org/10.2967/jnumed.122.263835.CrossRefPubMed

10.

Liu G, Mao W, Yu H, Hu Y, Gu J, Shi H. One-stop [(18)F]FDG and [(68)Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study. Eur J Nucl Med Mol Imaging. 2023;50(8):2271–81. https://doi.org/10.1007/s00259-023-06207-2.CrossRefPubMed

11.

Zheng Z, Gao H, Lin Y, Yu H, Mao W, Yang R, et al. The optimum earliest total-body 68Ga-FAPI-04 PET scan timing: an evidence-based single-centre study. Eur Radiol. 2024;34(7):4550–60. https://doi.org/10.1007/s00330-023-10264-4.CrossRefPubMed

12.

Yu H, Gu Y, Fan W, Gao Y, Wang M, Zhu X, et al. Expert consensus on oncological [(18)F]FDG total-body PET/CT imaging (version 1). Eur Radiol. 2023;33(1):615–26. https://doi.org/10.1007/s00330-022-08960-8.CrossRefPubMed

13.

ICRP. Radiation dose to patients from radiopharmaceuticals. Ann ICRP. 2008;38(1–2):1–197. https://doi.org/10.1016/j.icrp.2008.08.003. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007.

14.

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-Containing FAP-Targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386–92. https://doi.org/10.2967/jnumed.118.215913.CrossRefPubMedPubMedCentral

15.

Christner JA, Kofler JM, McCollough CH. Estimating effective dose for CT using dose-length product compared with using organ doses: consequences of adopting International Commission on Radiological Protection publication 103 or dual-energy scanning. AJR Am J Roentgenol. 2010;194(4):881–9. https://doi.org/10.2214/AJR.09.3462.CrossRefPubMed

16.

Calais J, Mona CE, Will. FAPI PET/CT replace FDG PET/CT in the next decade? Point-An important diagnostic, phenotypic, and biomarker role. AJR Am J Roentgenol. 2021;216(2):305–6. https://doi.org/10.2214/AJR.20.24302.CrossRefPubMed

17.

Gündoğan C, Güzel Y, Can C, Kaplan İ, Kömek H. FAPI-04 uptake in healthy tissues of cancer patients in (68)Ga-FAPI-04 PET/CT imaging. Contrast Media Mol Imaging. 2021;2021:9750080. https://doi.org/10.1155/2021/9750080.CrossRefPubMedPubMedCentral

18.

Altini C, Niccoli Asabella A, Di Palo A, Fanelli M, Ferrari C, Moschetta M, et al. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography. Med (Baltim). 2015;94(20):e864. https://doi.org/10.1097/MD.0000000000000864.CrossRef

19.

Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306(2):e220749. https://doi.org/10.1148/radiol.220749.CrossRefPubMed

Title: Exploration the feasibility and additional value of [18F]FDG/[68Ga]Ga-FAPI-04 dual-low-activity-tracer one-stop total-body PET imaging at 34 min post-injection of [68Ga]Ga-FAPI-04
Authors: Zhe Zheng
Yibo He
Wujian Mao
Haojun Yu
Ha Wu
Runjun Yang
Huaping Gao
Pengcheng Hu
Hongcheng Shi
Publication date: 25-09-2024
Publisher: Springer Berlin Heidelberg
Keywords: Positron Emission Tomography
Computed Tomography
Computed Tomography
Metastasis
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06924-2

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Exploration the feasibility and additional value of [¹⁸F]FDG/[⁶⁸Ga]Ga-FAPI-04 dual-low-activity-tracer one-stop total-body PET imaging at 34 min post-injection of [⁶⁸Ga]Ga-FAPI-04

Abstract

Objectives

Methods

Results

Conclusion

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content